MBX Biosciences Files 8-K for Bylaws and Financials
Ticker: MBX · Form: 8-K · Filed: Sep 16, 2024 · CIK: 1776111
Sentiment: neutral
Topics: corporate-governance, financials, filing
TL;DR
MBX Biosciences filed an 8-K for bylaw changes and financials. Standard stuff.
AI Summary
MBX Biosciences, Inc. filed an 8-K on September 16, 2024, reporting amendments to its Articles of Incorporation or Bylaws and filing financial statements and exhibits. The company, incorporated in Delaware with its principal executive offices in Carmel, Indiana, operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing indicates routine corporate updates and the submission of financial information, which is crucial for investors to assess the company's financial health and governance.
Risk Assessment
Risk Level: low — This is a routine filing for corporate updates and financial statements, not indicating any immediate significant risks or opportunities.
Key Numbers
- 001-42272 — SEC File Number (Identifies the company's filing with the SEC.)
- 84-1882872 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- MBX Biosciences, Inc. (company) — Registrant
- September 16, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Carmel, Indiana (location) — Principal executive offices
- 2834 (sic_code) — Standard Industrial Classification for Pharmaceutical Preparations
FAQ
What specific amendments were made to MBX Biosciences' Articles of Incorporation or Bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the summary of the 8-K filing itself, likely detailed within the attached exhibits.
What type of financial statements were filed with this 8-K?
The filing states that 'Financial Statements and Exhibits' were filed, but does not specify the period or type (e.g., quarterly, annual) of the financial statements.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on September 16, 2024.
What is MBX Biosciences, Inc.'s Standard Industrial Classification (SIC) code?
MBX Biosciences, Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Where are MBX Biosciences, Inc.'s principal executive offices located?
MBX Biosciences, Inc.'s principal executive offices are located at 11711 N. Meridian Street, Suite 300, Carmel, Indiana 46032.
Filing Stats: 759 words · 3 min read · ~3 pages · Grade level 12.3 · Accepted 2024-09-16 16:21:56
Key Financial Figures
- $0.0001 — e on which registered Common Stock, $0.0001 par value per share MBX Nasdaq Glob
Filing Documents
- d888081d8k.htm (8-K) — 20KB
- d888081dex31.htm (EX-3.1) — 29KB
- d888081dex32.htm (EX-3.2) — 119KB
- 0001193125-24-219621.txt ( ) — 170KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 3.1 Fourth Amended and Restated Certificate of Incorporation of MBX Biosciences, Inc. 3.2 Amended and Restated Bylaws of MBX Biosciences, Inc. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MBX Biosciences, Inc. Date: September 16, 2024 By: /s/ P. Kent Hawryluk P. Kent Hawryluk President and Chief Executive Officer